Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Liabilities (2016 - 2025)

Kiora Pharmaceuticals' Total Liabilities history spans 11 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 24.22% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, down 24.22%, while the annual FY2025 figure was $8.1 million, 24.22% down from the prior year.
  • Total Liabilities reached $8.1 million in Q4 2025 per KPRX's latest filing, up from $7.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $10.7 million in Q4 2024 to a low of -$2.6 million in Q2 2021.
  • Average Total Liabilities over 5 years is $6.5 million, with a median of $7.5 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: tumbled 181.52% in 2021, then surged 376.39% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $5.6 million in 2021, then rose by 28.64% to $7.1 million in 2022, then rose by 6.46% to $7.6 million in 2023, then soared by 41.07% to $10.7 million in 2024, then fell by 24.22% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Total Liabilities are $8.1 million (Q4 2025), $7.5 million (Q3 2025), and $9.8 million (Q2 2025).